Key Findings
- In a 3-month randomized controlled trial (55 participants), riboflavin 400 mg/day was associated with a significant reduction in migraine attack frequency (p=0.005) and headache days versus placebo.
- The proportion of "responders" (≥50% improvement) was 59% with riboflavin versus 15% with placebo.
- Benefit did not begin until after the first month and was greatest by month three, so consistent use matters.
- A later systematic review and meta-analysis supported a positive effect of vitamin B2 on migraine frequency, duration, and related measures.